WO2016109361A3 - 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase - Google Patents

3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase Download PDF

Info

Publication number
WO2016109361A3
WO2016109361A3 PCT/US2015/067543 US2015067543W WO2016109361A3 WO 2016109361 A3 WO2016109361 A3 WO 2016109361A3 US 2015067543 W US2015067543 W US 2015067543W WO 2016109361 A3 WO2016109361 A3 WO 2016109361A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxylase
benzonitrile
fluoro
inhibitors
beta
Prior art date
Application number
PCT/US2015/067543
Other languages
French (fr)
Other versions
WO2016109361A2 (en
Inventor
Chengzhi Zhang
Justin CHAKMA
Original Assignee
Auspex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals, Inc. filed Critical Auspex Pharmaceuticals, Inc.
Publication of WO2016109361A2 publication Critical patent/WO2016109361A2/en
Publication of WO2016109361A3 publication Critical patent/WO2016109361A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

The present invention relates to new 3-fluoro-benzonitrile modulators of 11-β- hydroxylase, pharmaceutical compositions thereof, and methods of use thereof.
PCT/US2015/067543 2014-12-31 2015-12-27 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase WO2016109361A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462098722P 2014-12-31 2014-12-31
US62/098,722 2014-12-31

Publications (2)

Publication Number Publication Date
WO2016109361A2 WO2016109361A2 (en) 2016-07-07
WO2016109361A3 true WO2016109361A3 (en) 2016-09-29

Family

ID=56285146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/067543 WO2016109361A2 (en) 2014-12-31 2015-12-27 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase

Country Status (3)

Country Link
AR (1) AR103354A1 (en)
TW (1) TW201625638A (en)
WO (1) WO2016109361A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
CN111592546B (en) * 2020-05-26 2023-08-25 上海鲲博玖瑞医药科技发展有限公司 Preparation method of adestat

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049616A1 (en) * 2005-08-25 2007-03-01 Ksander Gary M Organic compounds
WO2011064376A1 (en) * 2009-11-30 2011-06-03 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049616A1 (en) * 2005-08-25 2007-03-01 Ksander Gary M Organic compounds
WO2011064376A1 (en) * 2009-11-30 2011-06-03 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors

Also Published As

Publication number Publication date
TW201625638A (en) 2016-07-16
WO2016109361A2 (en) 2016-07-07
AR103354A1 (en) 2017-05-03

Similar Documents

Publication Publication Date Title
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
WO2016011222A3 (en) Circular polynucleotides
EP3139920A4 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
EP3129048A4 (en) Antibodies, pharmaceutical compositions and uses thereof
MX2020001756A (en) Benzoquinolone inhibitors of vmat2.
MX2018004674A (en) Modulators of sestrin-gator2 interaction and uses thereof.
EP3179983A4 (en) Anti-methanogenic compositions and uses thereof
WO2015120138A3 (en) AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
MX2017004808A (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis.
EP3157515A4 (en) Platinum compounds, compositions, and uses thereof
WO2015191945A3 (en) Solid state forms of sofosbuvir
EP3166892A4 (en) Scale-inhibition compositions and methods of making and using the same
EP3538189A4 (en) Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
EP3110891A4 (en) Low-voc compositions and methods of making and using the same
WO2016079110A3 (en) Use of enzyme for cleaning
WO2016020210A8 (en) Factor viii formulation
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
PL3468964T3 (en) Modulators of soce, compositions, and uses thereof
IN2014CH00840A (en)
EP3237391A4 (en) Creatine prodrugs, compositions and methods of use thereof
EP3538126A4 (en) Bacteriocin production, compositions and methods of use
EP3497077A4 (en) Amide compounds, pharmaceutical compositions thereof, and methods of using the same
EP3341006A4 (en) Compositions and methods for the treatment of neurodamage
EP3113774A4 (en) Compositions of grapiprant and methods for using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15876061

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 06.09.2017)

122 Ep: pct application non-entry in european phase

Ref document number: 15876061

Country of ref document: EP

Kind code of ref document: A2